Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP01 extension/compassionate-use study in progressive fibrosing interstitial lung disease
ACTRN12621000170820Phase 2Completed
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), sponsored by Avalyn Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Started Jun 2021; status: completed.
02
Drugs
pirfenidone
03
Conditions
progressive pulmonary fibrosis (PPF)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ACTRN12621000170820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000170820.